| Year |
Citation |
Score |
| 2022 |
Islam MT, Date K, Khan AI, Bhuiyan TR, Khan ZH, Ahmed S, Hossain M, Khaton F, Zaman K, McMillan NAJ, Anand A, An Q, Zhang C, Weldon WC, Yu A, et al. Co-administration of Oral Cholera Vaccine with Oral Polio Vaccine among Bangladeshi Young Children: A Randomized Controlled Open Label Trial to Assess Interference. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 36136760 DOI: 10.1093/cid/ciac782 |
0.522 |
|
| 2021 |
Bashorun AO, Badjie Hydara M, Adigweme I, Umesi A, Danso B, Johnson N, Sambou NA, Fofana S, Kanu FJ, Jeyaseelan V, Verma H, Weldon WC, Oberste MS, Sutter RW, Jeffries D, et al. Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia. The Lancet. Global Health. 10: e257-e268. PMID 34951974 DOI: 10.1016/S2214-109X(21)00497-6 |
0.522 |
|
| 2021 |
Gast C, Bandyopadhyay AS, Sáez-Llorens X, De Leon T, DeAntonio R, Jimeno J, Aguirre G, McDuffie LM, Coffee E, Mathis DL, Oberste MS, Weldon WC, Konopka-Anstadt JL, Modlin J, Bachtiar NS, et al. Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV/IPV-vaccinated infants: two randomized clinical trials. The Journal of Infectious Diseases. PMID 34610135 DOI: 10.1093/infdis/jiab507 |
0.577 |
|
| 2021 |
Wahid R, Mercer L, Macadam A, Carlyle S, Stephens L, Martin J, Chumakov K, Laassri M, Petrovskaya S, Smits SL, Stittelaar KJ, Gast C, Weldon WC, Konopka-Anstadt JL, Steven Oberste M, et al. Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. Npj Vaccines. 6: 94. PMID 34326330 DOI: 10.1038/s41541-021-00355-y |
0.496 |
|
| 2020 |
De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, De Smedt P, Aerssens A, Leroux-Roels G, Oberste MS, Konopka-Anstadt JL, Weldon WC, Fix A, Konz J, Wahid R, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet (London, England). PMID 33308429 DOI: 10.1016/S0140-6736(20)32541-1 |
0.519 |
|
| 2020 |
Sáez-Llorens X, Bandyopadhyay AS, Gast C, Leon T, DeAntonio R, Jimeno J, Caballero MI, Aguirre G, Oberste MS, Weldon WC, Konopka-Anstadt JL, Modlin J, Bachtiar NS, Fix A, Konz J, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet (London, England). PMID 33308427 DOI: 10.1016/S0140-6736(20)32540-X |
0.53 |
|
| 2020 |
Bandyopadhyay AS, Gast C, Rivera L, Sáez-Llorens X, Oberste MS, Weldon WC, Modlin J, Clemens R, Costa Clemens SA, Jimeno J, Rüttimann R. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. The Lancet. Infectious Diseases. PMID 33284114 DOI: 10.1016/S1473-3099(20)30555-7 |
0.417 |
|
| 2020 |
Tagbo BN, Verma H, Mahmud ZM, Ernest K, Nnani RO, Chukwubike C, Craig KT, Hamisu A, Weldon WC, Oberste SM, Jeyaseelan V, Braka F, Mkanda P, Esangbedo D, Olowu A, et al. Randomized Controlled Clinical Trial of bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children. The Journal of Infectious Diseases. PMID 33230550 DOI: 10.1093/infdis/jiaa726 |
0.488 |
|
| 2020 |
Bandyopadhyay AS, Gast C, Brickley EB, Rüttimann R, Clemens R, Oberste MS, Weldon WC, Ackerman ME, Connor RI, Wieland-Alter WF, Wright P, Usonis V. A randomized phase 4 study of immunogenicity and safety following monovalent oral type 2 Sabin polio vaccine challenge in IPV-vaccinated children in Lithuania. The Journal of Infectious Diseases. PMID 32621741 DOI: 10.1093/Infdis/Jiaa390 |
0.631 |
|
| 2020 |
Mansour Z, Said R, Wannemuehler K, Weldon W, Estephan J, Khachan J, Warrak R, Hendley W, Ehrhardt D, Farag NH. Estimating population immunity to poliovirus in Lebanon: Results from a seroprevalence survey, 2016. Vaccine. PMID 32499065 DOI: 10.1016/J.Vaccine.2020.05.052 |
0.464 |
|
| 2020 |
Voorman A, Habib MA, Hussain I, Muhammad Safdar R, Ahmed JA, Weldon WC, Ahmed I, Umer M, Partridge J, Soofi SB. Immunity and field efficacy of type 2-containing polio vaccines after cessation of trivalent oral polio vaccine: A population-based serological study in Pakistan. Vaccine: X. 5: 100067. PMID 32462141 DOI: 10.1016/j.jvacx.2020.100067 |
0.571 |
|
| 2020 |
Estivariz CF, Bennett SD, Lickness JS, Feldstein LR, Weldon WC, Leidman E, Ehlman DC, Khan MFH, Adhikari JM, Hasan M, Billah MM, Oberste MS, Alamgir ASM, Flora MD. Assessment of immunity to polio among Rohingya children in Cox's Bazar, Bangladesh, 2018: A cross-sectional survey. Plos Medicine. 17: e1003070. PMID 32231366 DOI: 10.1371/Journal.Pmed.1003070 |
0.45 |
|
| 2020 |
McDonald SL, Weldon WC, Wei L, Chen Q, Shaw J, Zhao K, Jorba J, Kew OM, Pallansch MA, Burns CC, Steven Oberste M. Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients. Vaccine. PMID 32089462 DOI: 10.1016/J.Vaccine.2020.02.035 |
0.639 |
|
| 2020 |
Stinson JA, Palmer CR, Miller DP, Li AB, Lightner K, Jost H, Weldon WC, Oberste MS, Kluge JA, Kosuda KM. Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine. Vaccine. PMID 31959422 DOI: 10.1016/J.Vaccine.2019.12.062 |
0.449 |
|
| 2019 |
Farag NH, Wannemuehler K, Weldon W, Arbaji A, Belbaisi A, Khuri-Bulos N, Ehrhardt D, Surour MR, ElhajQasem NS, Al-Abdallat MM. Estimating population immunity to poliovirus in Jordan's high-risk areas. Human Vaccines & Immunotherapeutics. PMID 31584319 DOI: 10.1080/21645515.2019.1667727 |
0.37 |
|
| 2019 |
Van Damme P, Coster I, Bandyopadhyay AS, Suykens L, Rudelsheim P, Neels P, Oberste MS, Weldon WC, Clemens R, Revets H. Poliopolis: pushing boundaries of scientific innovations for disease eradication. Future Microbiology. PMID 31482728 DOI: 10.2217/Fmb-2019-0196 |
0.618 |
|
| 2019 |
Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, Suykens L, Oberste MS, Weldon WC, Costa-Clemens SA, Clemens R, Modlin J, Weiner AJ, Macadam AJ, Andino R, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet (London, England). PMID 31174831 DOI: 10.1016/S0140-6736(19)31279-6 |
0.626 |
|
| 2019 |
Snider CJ, Zaman K, Estivariz CF, Yunus M, Weldon WC, Wannemuehler KA, Oberste MS, Pallansch MA, Wassilak SG, Bari TIA, Anand A. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. Lancet (London, England). PMID 31104832 DOI: 10.1016/S0140-6736(19)30503-3 |
0.483 |
|
| 2019 |
Joyce JC, Sella HE, Jost H, Mistilis MJ, Esser ES, Pradhan P, Toy R, Collins ML, Rota PA, Roy K, Skountzou I, Compans RW, Oberste MS, Weldon WC, Norman JJ, et al. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 31071375 DOI: 10.1016/J.Jconrel.2019.05.006 |
0.73 |
|
| 2019 |
Huyen DTT, Mach O, Trung NT, Thai PQ, Thang HV, Weldon WC, Oberste MS, Jeyaseelan V, Sutter RW, Anh DD. Rapid Disappearance of Poliovirus Type 2 Immunity in Young Children Following Withdrawal of Oral Poliovirus Type 2 Containing Vaccine in Vietnam. The Journal of Infectious Diseases. PMID 30869149 DOI: 10.1093/Infdis/Jiz124 |
0.645 |
|
| 2019 |
Harrison CJ, Weldon WC, Pahud BA, Jackson MA, Oberste MS, Selvarangan R. Neutralizing Antibody against Enterovirus D68 in Children and Adults before 2014 Outbreak, Kansas City, Missouri, USA. Emerging Infectious Diseases. 25: 585-588. PMID 30789123 DOI: 10.3201/Eid2503.180960 |
0.312 |
|
| 2019 |
Hsu CH, Wannemuehler KA, Soofi S, Mashal M, Hussain I, Bhutta ZA, McDuffie L, Weldon W, Farag NH. Poliovirus immunity among children under five years-old in accessible areas of Afghanistan, 2013. Vaccine. PMID 30782488 DOI: 10.1016/J.Vaccine.2019.02.008 |
0.491 |
|
| 2019 |
Gamage D, Mach O, Ginige S, Weldon WC, Oberste MS, Jeyaseelan V, Sutter RW. Poliovirus type 2 seroprevalence following full or fractional-dose of inactivated poliovirus vaccine in the period after Sabin type 2 withdrawal in Sri Lanka. The Journal of Infectious Diseases. PMID 30649505 DOI: 10.1093/Infdis/Jiz026 |
0.523 |
|
| 2019 |
Wang Y, Zade J, Moon SS, Weldon W, Pisal SS, Glass RI, Dhere RM, Jiang B. Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species. Vaccine. PMID 30626530 DOI: 10.1016/J.Vaccine.2018.12.043 |
0.653 |
|
| 2018 |
Gaensbauer JT, Gast C, Bandyopadhyay AS, O'Ryan M, Saez-Llorens X, Rivera L, Lopez-Medina E, Melgar M, Weldon WC, Oberste MS, Rüttimann R, Clemens R, Asturias EJ. Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 67: S57-S65. PMID 30376095 DOI: 10.1093/Cid/Ciy649 |
0.658 |
|
| 2018 |
Bhaumik SK, Kulkarni RR, Weldon WC, Silveira ELV, Ahmed H, Gunisetty S, Chandele A, Antia R, Verma H, Sutter R, Pallansch MA, Oberste MS, Villinger F, Orenstein W, Murali-Krishna K. Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 67: S66-S77. PMID 30376091 DOI: 10.1093/Cid/Ciy634 |
0.546 |
|
| 2018 |
Verma H, Iliyasu Z, Craig KT, Molodecky NA, Urua U, Jibir BW, Gwarzo GD, Gajida AU, McDonald S, Weldon WC, Oberste MS, Braka F, Mkanda P, Sutter RW. Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 67: S103-S109. PMID 30376090 DOI: 10.1093/Cid/Ciy637 |
0.52 |
|
| 2018 |
Brickley EB, Wieland-Alter W, Connor RI, Ackerman ME, Boesch AW, Arita M, Weldon WC, O'Ryan MG, Bandyopadhyay AS, Wright PF. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 67: S42-S50. PMID 30376086 DOI: 10.1093/Cid/Ciy603 |
0.645 |
|
| 2018 |
Gamage D, Mach O, Palihawadana P, Zhang Y, Weldon WC, Oberste MS, Gunasena S, Sutter RW. Boosting of mucosal immunity after fractional-dose inactivated poliovirus vaccine. The Journal of Infectious Diseases. PMID 29982532 DOI: 10.1093/Infdis/Jiy389 |
0.62 |
|
| 2018 |
Zaman K, Estívariz CF, Morales M, Yunus M, Snider CJ, Gary HE, Weldon WC, Oberste MS, Wassilak SG, Pallansch MA, Anand A. Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial. The Lancet. Infectious Diseases. PMID 29571817 DOI: 10.1016/S1473-3099(18)30113-0 |
0.598 |
|
| 2018 |
Razafindratsimandresy R, Mach O, Heraud JM, Bernardson B, Weldon WC, Oberste MS, Sutter RW. Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar. Heliyon. 4: e00563. PMID 29560473 DOI: 10.1016/J.Heliyon.2018.E00563 |
0.639 |
|
| 2018 |
White JA, Estrada M, Weldon WC, Chumakov K, Kouiavskaia D, Fournier-Caruana J, Stevens E, Gary HE, Maes EF, Oberste MS, Snider CJ, Anand A, Chen D. Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures. Biologicals : Journal of the International Association of Biological Standardization. PMID 29548791 DOI: 10.1016/J.Biologicals.2018.03.002 |
0.601 |
|
| 2018 |
Hussain I, Mach O, Hamid NA, Bhatti ZS, Moore DD, Oberste MS, Khan S, Khan H, Weldon WC, Sutter RW, Bhutta ZA, Soofi SB. Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017. Vaccine. PMID 29510918 DOI: 10.1016/J.Vaccine.2018.02.055 |
0.302 |
|
| 2018 |
Saleem AF, Yousafzai MT, Mach O, Khan A, Quadri F, Weldon WC, Oberste MS, Zaidi SS, Alam MM, Sutter RW, Zaidi AKM. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan. Vaccine. PMID 29477307 DOI: 10.1016/J.Vaccine.2018.02.051 |
0.602 |
|
| 2018 |
Guindo O, Mach O, Doumbia S, Ekra DK, Beavogui AH, Weldon WC, Oberste MS, Sutter RW. Assessment of poliovirus antibody seroprevalence in polio high risk areas of West Africa. Vaccine. PMID 29358054 DOI: 10.1016/J.Vaccine.2018.01.022 |
0.488 |
|
| 2018 |
Brickley EB, Strauch CB, Wieland-Alter WF, Connor RI, Lin S, Weiner JA, Ackerman ME, Arita M, Oberste MS, Weldon WC, Sáez-Llorens X, Bandyopadhyay AS, Wright PF. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine. The Journal of Infectious Diseases. PMID 29304199 DOI: 10.1093/Infdis/Jix556 |
0.633 |
|
| 2017 |
Bandyopadhyay AS, Asturias EJ, O'Ryan M, Oberste MS, Weldon W, Clemens R, Rüttimann R, Modlin JF, Gast C. Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules. Vaccine. PMID 29150209 DOI: 10.1016/J.Vaccine.2017.11.006 |
0.596 |
|
| 2017 |
Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Oberste MS, Zaidi SS, Alam MM, Quadri F, Sutter RW, Zaidi AKM. Immunogenicity of Different Routine Poliovirus Vaccination Schedules: a Randomized Controlled Trial, Karachi, Pakistan. The Journal of Infectious Diseases. PMID 29126173 DOI: 10.1093/Infdis/Jix577 |
0.532 |
|
| 2017 |
Muller DA, Fernando GJP, Owens NS, Agyei-Yeboah C, Wei JCJ, Depelsenaire ACI, Forster A, Fahey P, Weldon WC, Oberste MS, Young PR, Kendall MAF. High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses. Scientific Reports. 7: 12644. PMID 28974777 DOI: 10.1038/S41598-017-13011-0 |
0.514 |
|
| 2017 |
Gofama MM, Verma H, Abdullahi H, Molodecky NA, Craig KT, Urua UA, Garba MA, Alhaji MA, Weldon WC, Oberste MS, Braka F, Muhammad AJG, Sutter RW. Survey of poliovirus antibodies in Borno and Yobe States, North-Eastern Nigeria. Plos One. 12: e0185284. PMID 28949979 DOI: 10.1371/Journal.Pone.0185284 |
0.518 |
|
| 2017 |
Gofama MM, Verma H, Abdullahi H, Molodecky NA, Craig KT, Urua UA, Garba MA, Alhaji MA, Weldon WC, Oberste MS, Braka F, Muhammad AJG, Sutter RW. Survey of poliovirus antibodies in Borno and Yobe States, North-Eastern Nigeria. Plos One. 12: e0185284. PMID 28949979 DOI: 10.1371/journal.pone.0185284 |
0.434 |
|
| 2017 |
Voorman A, Hoff NA, Doshi RH, Alfonso V, Mukadi P, Muyembe-Tamfum JJ, Wemakoy EO, Bwaka A, Weldon W, Gerber S, Rimoin AW. Polio immunity and the impact of mass immunization campaigns in the Democratic Republic of the Congo. Vaccine. PMID 28882442 DOI: 10.1016/J.Vaccine.2017.08.063 |
0.544 |
|
| 2017 |
Hussain I, Mach O, Habib A, Bhatti Z, Suhag Z, Oberste MS, Weldon WC, Sutter RW, Soofi SB, Bhutta ZA. Seroprevalence of Anti-polio Antibodies in Children From Polio High-risk Areas of Pakistan: A Cross-Sectional Survey 2015-2016. The Pediatric Infectious Disease Journal. 36: e230-e236. PMID 28806355 DOI: 10.1097/Inf.0000000000001622 |
0.301 |
|
| 2017 |
Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Oberste MS, Sutter RW, Zaidi AKM. Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan. Vaccine. PMID 28479178 DOI: 10.1016/J.Vaccine.2017.04.075 |
0.536 |
|
| 2017 |
Lopez-Medina E, Melgar M, Gaensbauer JT, Bandyopadhyay AS, Borate BR, Weldon WC, Rüttimann R, Ward J, Clemens R, Asturias EJ. Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America. Vaccine. PMID 28455172 DOI: 10.1016/J.Vaccine.2017.04.041 |
0.561 |
|
| 2017 |
Upfill-Brown A, Taniuchi M, Platts-Mills JA, Kirkpatrick B, Burgess SL, Oberste MS, Weldon W, Houpt E, Haque R, Zaman K, Petri WA. Non-Specific Effects of Oral Polio Vaccine on Diarrheal Burden and Etiology among Bangladeshi Infants. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 28444240 DOI: 10.1093/Cid/Cix354 |
0.612 |
|
| 2017 |
Shaw J, Halsey NA, Weinberg A, Scott Schmid D, George KS, Weldon WC, Jordan M, Bryant PW, LaRussa PS, Bradshaw DY, Harrington T, Gershon A. Arm Paralysis After Routine Childhood Vaccinations: Application of Advanced Molecular Methods to the Causality Assessment of an Adverse Event After Immunization. Journal of the Pediatric Infectious Diseases Society. PMID 28339574 DOI: 10.1093/Jpids/Piw084 |
0.616 |
|
| 2017 |
Wallace GS, Pahud BA, Weldon WC, Curns AT, Oberste MS, Harrison CJ. Seroprevalence of Poliovirus Antibodies in the Kansas City metropolitan area, 2012-2013. Human Vaccines & Immunotherapeutics. 0. PMID 28059613 DOI: 10.1080/21645515.2016.1255386 |
0.525 |
|
| 2016 |
Habib MA, Soofi S, Mach O, Samejo T, Alam D, Bhatti Z, Weldon WC, Oberste MS, Sutter R, Bhutta ZA. Effect of booster doses of poliovirus vaccine in previously vaccinated children, Clinical Trial Results 2013. Vaccine. PMID 27269054 DOI: 10.1016/J.Vaccine.2016.05.065 |
0.63 |
|
| 2016 |
Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, Melgar M, Gaensbauer JT, Weldon WC, Oberste MS, Borate BR, Gast C, Clemens R, Orenstein W, G MO, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet (London, England). PMID 27212429 DOI: 10.1016/S0140-6736(16)00703-0 |
0.629 |
|
| 2016 |
Chan HT, Xiao Y, Weldon WC, Oberste SM, Chumakov K, Daniell H. Cold Chain and Virus Free chloroplast-made Booster Vaccine to Confer Immunity Against Different Polio Virus Serotypes. Plant Biotechnology Journal. PMID 27155248 DOI: 10.1111/Pbi.12575 |
0.608 |
|
| 2016 |
Cardemil CV, Estivariz C, Shrestha L, Sherchand JB, Sharma A, Gary HE, Oberste MS, Weldon WC, Bowen MD, Vinjé J, Schluter WW, Anand A, Mach O, Chu SY. The effect of diarrheal disease on bivalent oral polio vaccine (bOPV) immune response in infants in Nepal. Vaccine. PMID 27085172 DOI: 10.1016/J.Vaccine.2016.03.027 |
0.591 |
|
| 2016 |
Weldon WC, Oberste MS, Pallansch MA. Standardized Methods for Detection of Poliovirus Antibodies. Methods in Molecular Biology (Clifton, N.J.). 1387: 145-76. PMID 26983734 DOI: 10.1007/978-1-4939-3292-4_8 |
0.538 |
|
| 2016 |
Muller DA, Pearson FE, Fernando GJ, Agyei-Yeboah C, Owens NS, Corrie SR, Crichton ML, Wei JC, Weldon WC, Oberste MS, Young PR, Kendall MA. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. Scientific Reports. 6: 22094. PMID 26911254 DOI: 10.1038/Srep22094 |
0.567 |
|
| 2015 |
Naylor C, Lu M, Haque R, Mondal D, Buonomo E, Nayak U, Mychaleckyj JC, Kirkpatrick B, Colgate R, Carmolli M, Dickson D, van der Klis F, Weldon W, Steven Oberste M, et al. Environmental Enteropathy, Oral Vaccine Failure and Growth Faltering in Infants in Bangladesh. Ebiomedicine. 2: 1759-66. PMID 26870801 DOI: 10.1016/J.Ebiom.2015.09.036 |
0.485 |
|
| 2015 |
Sáez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SA, Weldon WC, Oberste MS, Molina N, Bandyopadhyay AS. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. The Lancet. Infectious Diseases. PMID 26719058 DOI: 10.1016/S1473-3099(15)00488-0 |
0.559 |
|
| 2015 |
Mychaleckyj JC, Haque R, Carmolli M, Zhang D, Colgate ER, Nayak U, Taniuchi M, Dickson D, Weldon WC, Oberste MS, Zaman K, Houpt ER, Alam M, Kirkpatrick BD, Petri WA. Effect of substituting IPV for tOPV on immunity to poliovirus in Bangladeshi infants: An open-label randomized controlled trial. Vaccine. PMID 26643930 DOI: 10.1016/J.Vaccine.2015.11.046 |
0.598 |
|
| 2015 |
van der Sanden SM, Wu W, Dybdahl-Sissoko N, Weldon WC, Brooks P, O'Donnell J, Jones LP, Brown C, Tompkins SM, Oberste MS, Karpilow J, Tripp RA. Engineering Enhanced Vaccine Cell Lines to Eradicate Vaccine-Preventable Diseases: The Polio Endgame. Journal of Virology. PMID 26581994 DOI: 10.1128/JVI.01464-15 |
0.534 |
|
| 2015 |
Anand A, Zaman K, Estívariz CF, Yunus M, Gary HE, Weldon WC, Bari TI, Steven Oberste M, Wassilak SG, Luby SP, Heffelfinger JD, Pallansch MA. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine. 33: 6816-22. PMID 26476367 DOI: 10.1016/J.Vaccine.2015.09.039 |
0.599 |
|
| 2015 |
O'Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, Clemens R, Orenstein W, Jimeno J, Rüttimann R, Costa Clemens SA, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. The Lancet. Infectious Diseases. 15: 1273-82. PMID 26318714 DOI: 10.1016/S1473-3099(15)00219-4 |
0.595 |
|
| 2015 |
Zhang Y, Moore DD, Nix WA, Oberste MS, Weldon WC. Neutralization of Enterovirus D68 isolated from the 2014 US outbreak by commercial intravenous immune globulin products. Journal of Clinical Virology : the Official Publication of the Pan American Society For Clinical Virology. 69: 172-5. PMID 26209401 DOI: 10.1016/J.Jcv.2015.06.086 |
0.341 |
|
| 2015 |
Gamage D, Palihawadana P, Mach O, Weldon WC, Oberste SM, Sutter RW. Achieving high seroprevalence against polioviruses in Sri Lanka-Results from a serological survey, 2014. Journal of Epidemiology and Global Health. 5: S67-71. PMID 26166424 DOI: 10.1016/J.Jegh.2015.06.004 |
0.572 |
|
| 2015 |
Estívariz CF, Anand A, Gary HE, Rahman M, Islam J, Bari TI, Wassilak SG, Chu SY, Weldon WC, Pallansch MA, Heffelfinger JD, Luby SP, Zaman K. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. The Lancet. Infectious Diseases. 15: 898-904. PMID 26093980 DOI: 10.1016/S1473-3099(15)00094-8 |
0.457 |
|
| 2015 |
Mir F, Quadri F, Mach O, Ahmed I, Bhatti Z, Khan A, Rehman NU, Durry E, Salama M, Oberste SM, Weldon WC, Sutter RW, Zaidi AK. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial. The Lancet. Infectious Diseases. PMID 26093979 DOI: 10.1016/S1473-3099(15)00093-6 |
0.6 |
|
| 2015 |
Saleem AF, Mach O, Quadri F, Khan A, Bhatti Z, Rehman NU, Zaidi S, Weldon WC, Oberste SM, Salama M, Sutter RW, Zaidi AK. Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan. Vaccine. 33: 2757-63. PMID 25917673 DOI: 10.1016/J.Vaccine.2015.04.055 |
0.493 |
|
| 2015 |
Norton EB, Bauer DL, Weldon WC, Oberste MS, Lawson LB, Clements JD. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine. 33: 1909-15. PMID 25765967 DOI: 10.1016/J.Vaccine.2015.02.069 |
0.617 |
|
| 2015 |
Edens C, Dybdahl-Sissoko NC, Weldon WC, Oberste MS, Prausnitz MR. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. Vaccine. 33: 4683-90. PMID 25749246 DOI: 10.1016/J.Vaccine.2015.01.089 |
0.576 |
|
| 2015 |
O'Ryan G M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, Clemens R, Orenstein W, Jimeno J, Rüttimann R, Costa Clemens SA. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: A randomised, controlled, open-label, phase 4, non-inferiority study The Lancet Infectious Diseases. DOI: 10.1016/S1473-3099(15)00219-4 |
0.507 |
|
| 2014 |
White JA, Blum JS, Hosken NA, Marshak JO, Duncan L, Zhu C, Norton EB, Clements JD, Koelle DM, Chen D, Weldon WC, Oberste MS, Lal M. Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Human Vaccines & Immunotherapeutics. 10: 3611-21. PMID 25483682 DOI: 10.4161/Hv.32253 |
0.585 |
|
| 2014 |
Cardemil CV, Jonas A, Gerber S, Weldon WC, Oberste MS, Beukes A, Sawadogo S, Patel SV, Zeko S, Muroua C, Gaeb E, Wannemuehler K, Goodson JL. Poliovirus immunity among pregnant females aged 15-44 years, Namibia, 2010. The Journal of Infectious Diseases. 210: S136-42. PMID 25316828 DOI: 10.1093/Infdis/Jiu086 |
0.516 |
|
| 2014 |
Verdijk P, Rots NY, van Oijen MG, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WA. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine. 32: 4938-44. PMID 25043278 DOI: 10.1016/J.Vaccine.2014.07.029 |
0.473 |
|
| 2014 |
Haque R, Snider C, Liu Y, Ma JZ, Liu L, Nayak U, Mychaleckyj JC, Korpe P, Mondal D, Kabir M, Alam M, Pallansch M, Oberste MS, Weldon W, Kirkpatrick BD, et al. Oral polio vaccine response in breast fed infants with malnutrition and diarrhea. Vaccine. 32: 478-82. PMID 24300591 DOI: 10.1016/J.Vaccine.2013.11.056 |
0.547 |
|
| 2012 |
Weldon WC, Zarnitsyn VG, Esser ES, Taherbhai MT, Koutsonanos DG, Vassilieva EV, Skountzou I, Prausnitz MR, Compans RW. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. Plos One. 7: e41501. PMID 22848514 DOI: 10.1371/Journal.Pone.0041501 |
0.716 |
|
| 2012 |
del Pilar Martin M, Weldon WC, Zarnitsyn VG, Koutsonanos DG, Akbari H, Skountzou I, Jacob J, Prausnitz MR, Compans RW. Local response to microneedle-based influenza immunization in the skin. Mbio. 3: e00012-12. PMID 22396479 DOI: 10.1128/Mbio.00012-12 |
0.674 |
|
| 2011 |
Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, Prausnitz MR, Compans RW. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clinical and Vaccine Immunology : Cvi. 18: 647-54. PMID 21288996 DOI: 10.1128/Cvi.00435-10 |
0.718 |
|
| 2010 |
Weldon WC, Wang BZ, Martin MP, Koutsonanos DG, Skountzou I, Compans RW. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. Plos One. 5. PMID 20824188 DOI: 10.1371/Journal.Pone.0012466 |
0.68 |
|
| 2010 |
Skountzou I, Koutsonanos DG, Kim JH, Powers R, Satyabhama L, Masseoud F, Weldon WC, Martin Mdel P, Mittler RS, Compans R, Jacob J. Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. Journal of Immunology (Baltimore, Md. : 1950). 185: 1642-9. PMID 20585035 DOI: 10.4049/Jimmunol.1000091 |
0.547 |
|
| 2010 |
Skountzou I, Martin Mdel P, Wang B, Ye L, Koutsonanos D, Weldon W, Jacob J, Compans RW. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine. 28: 4103-12. PMID 19654062 DOI: 10.1016/J.Vaccine.2009.07.058 |
0.69 |
|
| 2007 |
Sloan SE, Hanlon C, Weldon W, Niezgoda M, Blanton J, Self J, Rowley KJ, Mandell RB, Babcock GJ, Thomas WD, Rupprecht CE, Ambrosino DM. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine. 25: 2800-10. PMID 17240489 DOI: 10.1016/J.Vaccine.2006.12.031 |
0.353 |
|
| 2006 |
Goudsmit J, Marissen WE, Weldon WC, Niezgoda M, Hanlon CA, Rice AB, Kruif Jd, Dietzschold B, Bakker AB, Rupprecht CE. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. The Journal of Infectious Diseases. 193: 796-801. PMID 16479514 DOI: 10.1086/500470 |
0.455 |
|
| 2005 |
Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Niezgoda M, Hanlon CA, Thijsse S, Backus HH, de Kruif J, Dietzschold B, Rupprecht CE, Goudsmit J. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. Journal of Virology. 79: 9062-8. PMID 15994800 DOI: 10.1128/Jvi.79.14.9062-9068.2005 |
0.316 |
|
| 2005 |
Kramer RA, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van der Horst M, Bakker AQ, de Jong M, Jongeneelen M, Thijsse S, Backus HH, Rice AB, Weldon WC, Rupprecht CE, Dietzschold B, Bakker AB, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. European Journal of Immunology. 35: 2131-45. PMID 15971273 DOI: 10.1002/Eji.200526134 |
0.366 |
|
| 2005 |
Hanlon CA, Kuzmin IV, Blanton JD, Weldon WC, Manangan JS, Rupprecht CE. Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Research. 111: 44-54. PMID 15896401 DOI: 10.1016/J.Virusres.2005.03.009 |
0.594 |
|
| 2005 |
Marissen WE, Kramer RA, Rice A, Weldon WC, Niezgoda M, Faber M, Slootstra JW, Meloen RH, Clijsters-van der Horst M, Visser TJ, Jongeneelen M, Thijsse S, Throsby M, de Kruif J, Rupprecht CE, et al. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. Journal of Virology. 79: 4672-8. PMID 15795253 DOI: 10.1128/Jvi.79.8.4672-4678.2005 |
0.344 |
|
| Show low-probability matches. |